Effects of chemotherapeutic agents on alpha-fetoprotein secretion and growth of human hepatoma cell lines in vitro

A. Muraoka, T. Tokiwa & J. Sato
Division of Pathology, Cancer Institute, Okayama University Medical School, 2-5-1 Shikata-cho, Okayama 700, Japan.

Summary The effects of various chemotherapeutic agents on alpha-fetoprotein (AFP) secretion and growth of human hepatocellular carcinoma and hepatoblastoma cell lines were investigated in vitro. It was found that there was a high correlation between hepatoma cell number and AFP secretion after treatment and that the amount of AFP secreted per cell per 72 h was notable for whole tumour but with that of viable tumour mass, and that AFP-secreting capacity of tumour cells in the mass is kept unchanged after chemotherapy.

Serum level of alpha-fetoprotein (AFP) is often increased in patients with hepatocellular carcinoma (HCC) or hepatoblastoma, and therefore the expression of AFP has served as a reliable tumour marker for diagnosis or therapy of HCC or hepatoblastoma. Many studies have been concerned with the correlation between AFP levels and tumour mass in patients (Johnson & Williams, 1980; Pritchard et al., 1982) or animals (Lo et al., 1973; Tsukada et al., 1974; Sell et al., 1974) with hepatoma. The relationship of serum AFP concentration to tumour mass was examined using human hepatocellular carcinoma cell line PLC/PRF/5-bearing nude mice, for the purpose of validating the use of changes in serum AFP level as a means of following response to therapy, and it was concluded that there was a positive correlation between serum AFP level and total tumour burden (Bassendine et al., 1983). However, it seemed to be difficult to estimate whether or not the AFP-producing capacity of hepatoma cells was affected by treatment with chemotherapeutic agents from their whole tumour study.

We examined in this study the change of secretion of AFP and that of cell number by treatment of human hepatocellular carcinoma and hepatoblastoma cells with various chemotherapeutic agents in vitro.

Materials and methods

Cell lines

Human well-differentiated hepatocellular carcinoma (HuH-7) (Nakabayashi et al., 1982) and well-differentiated hepatoblastoma (HuH-6) (Doi, 1976) cell lines were used. The population doubling times of HuH-7 and HuH-6 were 46.3 h and 83.1 h, respectively. The culture media used were RPMI-1640 (Nissui-Seiyaku, Japan) supplemented with 0.2% lactalbumin hydrolysate (Difco) and 2% bovine serum (BS) with 60 μg ml⁻¹ of kanamycin sulphate (Meiji-Seika, Japan). All dishes were kept at 37°C in a humidified atmosphere of 5% CO₂ and 95% air.

Chemotherapeutic agents

Mitomycin C (MMC), Adriamycin (ADM), 5-fluorouracil (5-FU) (Kyowa-Hakko, Japan) and cisplatinum (CDDP) (Nihon-Kayaku, Japan), which have been commonly used for the clinical treatment of hepatomas, were used as test agents. All agents were diluted to final concentration in the fresh medium and were used immediately for the experiment. Cultured cells were treated with chemotherapeutic agents to at least four concentrations including the therapeutically achievable range, which is one-tenth the peak plasma concentration in human pharmacokinetics studies (3 × 10⁻⁴ M for MMC, 7 × 10⁻⁸ M for 5-FU, 6 × 10⁻⁷ M for CDDP and 5 × 10⁻⁷ M for 5-FU) (Von Hoff et al., 1981).

Cell growth and AFP determination

Cells were inoculated into 24 multi-well cluster dishes (Falcon) coated with type I collagen (20 μg ml⁻¹) (Nitta gelatin, Japan) at densities of 5 × 10⁴ cells per well (HuH-7) or 8 × 10⁴ cells per well (HuH-6). Three days after plating, they were treated with chemotherapeutic agents for 30 min at 37°C, and then rinsed with PBS. The culture media were renewed every 3 days. Three and 6 days after treatment the cells were dispersed into single cell suspensions with 0.2% trypsin containing 0.02% EDTA and cell numbers were counted with the aid of a Coulter counter. Study was performed in triplicate. The spent media obtained from HuH-6 and HuH-7 were centrifuged (3000 g, 10 min) and the amount of AFP in the supernatant was determined by enzyme-linked immunosorbent assay (ELISA) using rabbit antihuman AFP and horse radish peroxidase-conjugated rabbit antihuman AFP antibodies (Dako) (Tokiwa et al., 1988). The limits of detection in ELISA were 1.0 ng per tube. The growth medium had no detectable AFP.

Statistics

Statistical analyses were performed using Student's t test.

Results

AFP secretion and cell growth

Figures 1 (HuH-7) and 2 (HuH-6) show the amounts of AFP secreted per well per 72 h and growth of cells treated with chemotherapeutic agents. The level of AFP secreted by HuH-7 was about twice that secreted by HuH-6. All the agents used inhibited dose-dependently not only cell growth but also the secretion of AFP. HuH-6 was generally more resistant to the 4 agents used than HuH-7. Figures 3 and 4 represent the correlation between growth inhibition and AFP secretion per well per 72 h. Most data points for HuH-6 were clustered towards control values. The correlation coefficient (r) of HuH-7, which was calculated from the data on day 3, day 6 and whole data after treatment, was 0.87 (P<0.01), 0.92 (P<0.01) and 0.91 (P<0.01), respectively. The correlation coefficient (r) of HuH-6 was 0.85 (P<0.01), 0.86 (P<0.01) and 0.88 (P<0.01), respectively. No significant difference was found between correlation coefficient of day 3 and that of day 6 in the two cell lines. Concerning the difference of chemotherapeutic agents, the correlation coefficient of HuH-7 treated with MMC, ADM, CDDP and 5-FU was 0.89 (P<0.01), 0.83 (P<0.01), 0.85 (P<0.01) and 0.59
per 10^4 cells per 72 h was reduced or increased by treatment of cells with ADM at above 10^{-8} M, with MMC at above 10^{-5} M or with CDDP at above 10^{-4} M.

| Table I | The amount of AFP 10^4 cells^{-1} 72 h^{-1} after treatment of HuH-7 |
|---------|---------------------------------------------------------------|
| Agent   | Concentration (log M) | Day 3 after treatment | Day 6 after treatment |
| MMC     | Control              | 507 ± 44              | 582 ± 72              |
|         | −8                   | 600 ± 55              | 563 ± 61              |
|         | −7                   | 540 ± 40              | 601 ± 55              |
|         | −6                   | 569 ± 102             | 719 ± 36              |
|         | −5                   | 600 ± 133             | 812 ± 96*             |
| ADM     | Control              | 538 ± 64              | 866 ± 136             |
|         | −8                   | 817 ± 211             | 649 ± 64              |
|         | −7                   | 648 ± 59              | 988 ± 228             |
|         | −6                   | 716 ± 81              | 860 ± 272             |
|         | −5                   | 543 ± 170             | 387 ± 24*             |
| CDDP    | Control              | 392 ± 28              | 648 ± 97              |
|         | −7                   | 400 ± 37              | 578 ± 15              |
|         | −6                   | 390 ± 72              | 869 ± 159             |
|         | −5                   | 470 ± 37              | 908 ± 98*             |
|         | −4                   | 264 ± 68*             | 426 ± 68*             |
| S-FU    | Control              | 435 ± 133             | 571 ± 102             |
|         | −7                   | 393 ± 31              | 579 ± 21              |
|         | −6                   | 513 ± 35              | 620 ± 77              |
|         | −5                   | 639 ± 54              | 609 ± 118             |
|         | −4                   | 618 ± 130             | 430 ± 91              |
|         | −3                   | 473 ± 54              | 418 ± 33              |

Data represent the mean±s.d. (n=3-6).

| Table II | The amount of AFP 10^4 cells^{-1} 72 h^{-1} after treatment of HuH-6 |
|----------|---------------------------------------------------------------|
| Agent    | Concentration (log M) | Day 3 after treatment | Day 6 after treatment |
| MMC      | Control              | 234 ± 29              | 313 ± 43              |
|          | −8                   | 216 ± 20              | 344 ± 12              |
|          | −7                   | 165 ± 7*              | 244 ± 3               |
|          | −6                   | 194 ± 37              | 268 ± 41              |
|          | −5                   | 282 ± 6               | 463 ± 25*             |
| ADM      | Control              | 142 ± 6               | 237 ± 37              |
|          | −8                   | 132 ± 13              | 171 ± 20              |
|          | −7                   | 129 ± 12              | 170 ± 14              |
|          | −6                   | 154 ± 7*              | 243 ± 22              |
|          | −5                   | 255 ± 21*             | 784 ± 146*            |
| CDDP     | Control              | 191 ± 27              | 329 ± 39              |
|          | −7                   | 190 ± 32              | 329 ± 1               |
|          | −6                   | 177 ± 31              | 260 ± 14              |
|          | −5                   | 187 ± 22              | 237 ± 11*             |
|          | −4                   | 376 ± 30*             | 1051 ± 98*            |
| S-FU     | Control              | 198 ± 20              | 227 ± 36              |
|          | −7                   | 202 ± 16              | 219 ± 22              |
|          | −6                   | 181 ± 16              | 212 ± 8               |
|          | −5                   | 184 ± 4               | 193 ± 3               |
|          | −4                   | 181 ± 10              | 181 ± 12              |
|          | −3                   | 158 ± 8               | 170 ± 20              |

Data represent the mean±s.d. (n=3-6).

*Significantly different from control (P<0.01).
Discussion

AFP has been a useful tool for diagnosis and indicator after treatment such as surgical operation, chemotherapy, transcatheter arterial embolization (TAE), hyperthermia and so on (Matsumoto et al., 1974; McIntire et al., 1976; Johnson et al., 1978). There are some early reports including studies on choriocarcinomas that serum or tumour AFP level does not correlate with tumour mass (Purves et al., 1970; Masseyeff, 1978; Raghavan et al., 1980). On the other hand, positive correlations between them have also been demonstrated by patient studies (Johnson & Williams, 1980) or model systems where mice transplanted with a human hepatocellular carcinoma cell line PLC/PRF/5 were used (Bassendine et al., 1983; Curtin et al., 1986). In the latter study, however, it seemed to be difficult to obtain reliable estimates of viable tumour mass and the amount of AFP secreted per cell because of the inclusion of many necrotic portions, especially after treatment. Thus, highly AFP-producing human hepatoma cell lines seem to be a suitable model for investigation of the growth capacity of cells or the amount of AFP secreted per cell. Few cell lines, however, have been available for such studies so far. The present studies were carried out using two human hepatocellular carcinoma and hepatoblastoma cell lines which were established in our laboratory and retained high AFP-producing capacity even in culture. These results show: (a) that there is a high correlation between tumour cell number and AFP secretion after treatment in vitro, corresponding to the data that were obtained by the patient studies or model systems described above; and (b) that the amount of AFP secreted per cell was not affected, with only one exception, by the treatment of cells with therapeutically achievable concentrations of chemotherapeutic agents, but affected with higher concentrations of some agents. These data suggest that serum AFP level in patients correlates with the size of viable tumour mass rather than that of whole tumour, and that AFP-secreting capacity of tumour cells in the tumour mass is kept unchanged after chemotherapy. Chemotherapeutic agents at above 10^-4 M seem to be toxic to the cells. In fact, many non-viable or morphological impaired cells were observed at these concentrations (data not shown). It seems likely that the data at higher concentration do not reflect exactly the AFP-secreting capacity of cells.

Not only therapeutically achievable concentration, but also area under the concentration curve (AUC) are important as pharmacokinetic parameters of drug behaviour (Salmon, 1984; Slec et al., 1986). The AUC is defined as the product of concentration and exposure time. It was found that the concentrations used in the present study were still valid by using these AUCs.

Despite the development of diagnosis, world-wide primary hepatomas have been one of the most lethal diseases (Liver Cancer Study Group of Japan, 1984; Dunk et al., 1988), and the exploitation of new effective chemotherapeutic agents has been needed. In vitro culture systems using highly AFP-producing hepatoma cell lines may provide a new drug screening model for hepatomas.

References

BASSENDINE, M. F., WRIGHT, N. A., THOMAS, H. C. & SHERLOCK, S. (1983). Growth characteristics of a-fetoprotein-secreting human hepatocellular carcinoma in athymic (nude) mice. Clin. Sci., 64, 643.

CURTIN, N.J., HARRIS, A.L., JAMES, O.F.W. & BASSENDINE, M.F. (1986). Inhibition of the growth of human hepatocellular carcinoma in vitro and in athymic mice by quinazoline inhibitor of thymidylate synthase, CB317. Br. J. Cancer, 53, 361.

DOI, I. (1976). Establishment of a cell line and its clonal sublines from a patient with hepatoblastoma. Gann, 67, 1.

DUNK, A.A., SPILIADIS, H., SHERLOCK, S. and 4 others (1988). Hepatocellular carcinoma: clinical, aetiological and pathological features in British patients. Int. J. Cancer, 41, 17.

JOHNSON, P.J., WILLIAMS, R., THOMAS, H., SHERLOCK, S. & MURRAY-LYON, I.M. (1978). Induction of remission in hepatocellular carcinoma with doxorubicin. Lancet, I, 1006.

JOHNSON, P.J. & WILLIAMS, R. (1980). Serum alpha-fetoprotein estimations and doubling time in hepatocellular carcinoma: influence of therapy and possible value in early detection. J. Natl Cancer Inst., 64, 1329.
LIVER CANCER STUDY GROUP OF JAPAN (1984). Primary liver cancer in Japan. Cancer, 54, 1747.
LO, K.W., MILLER, E.E., MORRIS, H.P. & TSOU, K.C. (1973). Chemotherapy of Morris hepatoma 3924A: correlation of size and weight of tumor and preliminary data with 5-fluoro-2'-deoxyuridine (5-FUDR: NSC-27640). Cancer Chemother. Rep., 57, 245.
MASSEYEFF, R.F. (1978). Factors influencing α-fetoprotein biosynthesis in patients with primary liver cancer and other disease. Gann Monogr. Cancer Res. 14, 3.
MATSUMOTO, Y., SUZUKI, T., ONO, H., NAKASE, A. & HONJO, I. (1974). Response of alpha-fetoprotein to chemotherapy in patients with hepatomas. Cancer, 34, 1602.
McINTIRE, K.R., VOGEL, C.L., PRIMACK, A., WALDMANN, T.A. & KYALWAZI, S.K. (1976). Effect of surgical and chemotherapeutic treatment on alpha-fetoprotein levels in patients with hepatocellular carcinoma. Cancer, 37, 677.
NAKABAYASHI, H., TAKETA, K., MIYANO, K., YAMANE, T. & SATO, J. (1982). Growth of human hepatoma cell lines with differentiated functions in chemically defined medium. Cancer Res., 42, 3858.
PRITCHARD, J., DA CUNHA, A., CORNBLEET, M.A. & CARTER, C.J. (1982). Alpha feto (aFP) monitoring of response to adriamycin in hepatoblastoma. J. Pediatr. Surg., 17, 429.
PURVES, L.R., BERSOHN, J. & GEDDES, E.W. (1970). Serum α-fetoprotein and primary cancer of the liver in man. Cancer, 25, 1261.
RAGHAVAN, D., GIBBS, J., COSTA, R.N. and 4 others (1980). The interpretation of marker protein assays: a critical appraisal in clinical studies and a xenograft model. Br. J. Cancer. 41, suppl. IV, 191.
SALMON, S.E. (1984). Human tumor colony assay and chemosensitivity testing. Cancer Treat. Rep., 68, 117.
SELL, S., WEPSIC, H.T., NICKEL, R. & NICHOLS, M. (1974). Rat alpha, fetoprotein. IV. Effect of growth and surgical removal of Morris hepatoma 7777 on the serum a,F concentration of buffalo rats. J. Natl Cancer Inst., 52, 133.
SLEE, P.H.T., DE BRUIN, E.A., LEEFLANG, P., KUPPEN, P.J.K., VAN DEN BERG, L. & VAN OOSTEROM, A.T. (1986). Variations in exposure to mitomycin C in an in vitro colony-forming assay. Br. J. Cancer, 54, 951.
TOKIWA, T., MIYAGIWA, M., KUSAKA, Y., MURAOKA, A. & SATO, J. (1988). Effects of various substrates on human hepatoblastoma and hepatoma cell culture. Cell Biol. Int. Rep., 12, 131.
TSUKADA, Y., MIKUNI, M. & HIRAL, H. (1974). In vitro cloning of a rat ascites hepatoma cell line, AH66, with special reference to alpha-fetoprotein synthesis. Int. J. Cancer, 13, 196.
VON HOFF, D.D., CASPER, J., BRADLEY, E., SANDBACH, J., JONES, D. & MAKUCH, R. (1981). Association between human tumor colony-forming assay results and response of an individual patient’s tumor to chemotherapy. Am. J. Med., 70, 1027.